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EBV, MSI, HM-SNV, CIN, and GS
d Hypermutated tumors had diverse immune features varying
by tissue and subtype
d CIN tumors displayed more fragmented copy-number
alterations in the upper GI tract
d Genome-stable CRC subtype was enriched for recurrent
mutations in SOX9 and PCBP1Liu et al., 2018, Cancer Cell 33, 721–735
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In Brief
Liu et al. analyze 921 gastrointestinal (GI)
tract adenocarcinomas and find that
hypermutated tumors are enriched for
insertions/deletions, upper GI tumors
with chromosomal instability harbor
fragmented genomes, and a group of
genome-stable colorectal tumors are
enriched in mutations in SOX9
and PCBP1.
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https://doi.org/10.1016/j.ccell.2018.03.010SUMMARYWe analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to examine shared and
distinguishing molecular characteristics of gastrointestinal tract adenocarcinomas (GIACs). Hypermutated
tumors were distinct regardless of cancer type and comprised those enriched for insertions/deletions,
representing microsatellite instability cases with epigenetic silencing of MLH1 in the context of CpG island
methylator phenotype, plus tumors with elevated single-nucleotide variants associated with mutations in
POLE. Tumors with chromosomal instability were diverse, with gastroesophageal adenocarcinomas
harboring fragmented genomes associated with genomic doubling and distinct mutational signatures. We
identified a group of tumors in the colon and rectum lacking hypermutation and aneuploidy termed genome
stable and enriched in DNA hypermethylation and mutations in KRAS, SOX9, and PCBP1.Significance
Adenocarcinomas of the gastrointestinal tract share not only a poor prognosis but also conserved molecular features. Hy-
permutated tumors display diverse immune features depending on tissue origin and molecular subtype, with implications
for targeted immunotherapeutics. Upper GI tumors with chromosomal instability display a fine genome fragmentation en-
riched for high amplitude, focal somatic copy-number alterations associated with whole-genome doubling, specific muta-
tional signatures, and advanced stage. We identified a genome-stablemolecular subtype among colorectal cancers with an
elevated frequency of recurrent mutations in SOX9 and PCBP1.
Cancer Cell 33, 721–735, April 9, 2018 ª 2018 Elsevier Inc. 721
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION
Traditional classifications of tumors have utilized tissue of
origin and histologic types. These categories have been refined
with comprehensive molecular characterizations across large
numbers of tumors. Adenocarcinomas of the gastrointestinal (GI)
tract share similar endodermal developmental origins and expo-
sure to common insults that promote tumor formation.We sought
to evaluatemolecular characteristics that distinguishGI tract ade-
nocarcinomas (GIACs) from other cancers and to investigate the
molecular features of GIACs across anatomic boundaries to pro-
vide insight into the pathogenesis of these deadly malignancies.
Approximately 1.4 million people die each year worldwide
from adenocarcinomas of the esophagus, stomach, colon, or
rectum (Arnold et al., 2015; Torre et al., 2016). Non-surgical treat-
ment approaches have made only modest progress over the
past half-century, inspiring efforts to better understand the bio-
logical basis of these cancers as a foundation for improving pre-
vention, screening, and therapy. Prior studies that separately
evaluated GIACs of the upper (gastroesophageal) and lower
(colorectal) GI tract found subgroups such as chromosomal
instability (CIN), microsatellite instability (MSI), and tumors with
hypermethylation phenotypes. However, systematic efforts to
characterize how shared molecular processes present differ-
ently across the GI tract have not been undertaken.
RESULTS
TheCancer GenomeAtlas Network obtained fresh frozen tissues
from 921 primary GIACs (79 esophageal, 383 gastric, 341 colon,
and 118 rectal cancers) without prior chemotherapy or radio-
therapy. All patients provided informed consent, and collections
were approved by local institutional review boards. Adjacent
non-malignant tissues were obtained from 76 patients. We
characterized samples by SNP array profiling for somatic
copy-number alterations (SCNAs), whole-exome sequencing,
array-based DNA methylation profiling, mRNA sequencing,
microRNA sequencing, and, for a subset of samples, reverse-
phase protein array (RPPA) profiling. Key characteristics of tu-
mor samples are summarized in Table S1.
Shared Features of GIACs
We investigated whether GIACs share characteristic molecular
features compared with other adenocarcinomas (Table S2).
Joint analysis of GIACs together with adenocarcinomas from
the breast (n = 1001), endometrium (506), cervix (24), bile
ducts (33), lung (240), pancreas (183), prostate (381), and ovaries
(503) revealed that GIACs clustered together by DNA hyperme-
thylation profiles (Figure S1A), mRNA (Figure S1B), and RPPA
(Figure S1C). These results are consistent with integrated
clustering analysis across multiple platforms of 10,000 TCGA
tumors, which identified GIACs as a distinct group (Hoadley
et al., 2018).
Genes mutated significantly more frequently in GIACs
compared with non-GI adenocarcinomas (non-GIACs) included
FBXW7, SMAD2, SOX9, and PCBP1 (Figure 1A; Table S3).
A GIAC-focused analysis revealed that ATM, PZP, CACNA1C,
and FBN3 were significantly mutated genes not previously
reported in TCGA studies of single cancer types (Figure S1D;722 Cancer Cell 33, 721–735, April 9, 2018Table S3). We evaluated SCNA data to identify amplifications
anddeletionsmorecommon inGIACs than in non-GIACs (Figures
1B and S1E; Table S4). Arm-level gain of chromosome 13q was
GIAC specific (Figure S1F), noteworthy as this region containing
tumor suppressor RB1 is often deleted in non-GIACs. CDX2
(13q12.2) and KLF5 (13q22.1) encoding two transcription factors
in this amplified region may contribute to GIAC pathogenesis.
Other genes preferentially amplified in GIACs included CDK6
(7q21.2), GATA6 (18q11.2), GATA4 (8p23.1), EGFR (7p11.2),
CD44 (11p13), BCL2L1 (20q11.21), FGFR1 (8p11.22), and IGF2
(11p15.5).APC and SOX9 deletions were observed preferentially
in GIACs, as were frequent mutations in these genes.
GIACs displayed markedly higher frequencies of CpG island
hypermethylation than did non-GIACs (Figure 1C, upper graphs).
This finding is attributable in part to the high frequency of CpG
island methylator phenotype (CIMP) in GIACs, but was also
evident in non-CIMP tumors. The average density of somatic
mutations was also higher in GIACs. Clusters of tumors with
high mutation densities were observed in gastric and colorectal
GIACs as well as in breast and uterine non-GIACs (Figure 1C,
middle graphs). Frequent SCNAs were observed in all GIACs,
especially in esophageal adenocarcinomas (EACs), and ovarian
and a subset of breast non-GIACs (Figure 1C, bottom graphs).
Gene expression analysis revealed 553 genes that were differ-
entially expressed in GIACs compared with non-GIACs, after
exclusion of genes that differed among corresponding normal
tissues (Figure S1G; Table S5). Supervised multivariate orthog-
onal partial least-squares discriminant analysis ranked 51 of
these 553 genes to have significantly higher expression in
GIACs. Notably, these genes include several that have roles
in gastrointestinal stem cell biology (e.g., OLFM4, CD44, and
KLF4) and genes related to the EGFR signaling pathway
(Figure S1G).
We next investigated whether genes encoding 139 transcrip-
tion factors that are important in GI development (Noah et al.,
2011; Sherwood et al., 2009) displayed distinct gain- or loss-
of-function events in GIACs compared with non-GIACs. Amplifi-
cations were considered gain-of-function (GOF) events, while
deletions, epigenetic silencing, and nonsense or indel mutations
were considered loss-of-function (LOF) events (Table S6). We
found 33 transcription factor genes with GOF or LOF exceeding
5% in at least one GIAC tumor type (Figure 1D).CDX2 encodes a
homeobox transcription factor expressed early in endoderm
development with evidence as either a lineage-survival onco-
gene (Salari et al., 2012) or a tumor-suppressor gene (Bon-
homme et al., 2003) in colorectal cancers (CRCs), depending
on context, and is also a marker of intestinal metaplasia in Bar-
rett’s esophagus (Moons et al., 2004). Interestingly, we observed
CDX2 amplification in esophageal, colon, and rectal adenocarci-
nomas, but LOF in gastric cancers. Although amplifications in
the genomic locus containing the stem cell transcription factor
KLF5 gene were found in all GIACs, these amplifications were
associated with increased stemness only in EACs based on a
gene-expression signature (Malta et al., 2018) (Figure S1H).
Molecular Subtypes within GIACs
Other studies have relied on gene expression, oncogenic
pathway, or histopathological criteria for subtype delineation
among GIACs (Budinska et al., 2013; Cristescu et al., 2015;
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Figure 1. Genomic Features of Gastrointestinal Adenocarcinomas
(A) Significantly mutated genes in gastrointestinal adenocarcinomas (GIACs) indicated by green circles, significantly mutated genes identified in other adeno-
carcinomas (non-GIACs) indicated by red circles, and genes identified as significantly mutated in all adenocarcinomas indicated by gold circles.
(B) Genes identified as significantly recurrently amplified (left) or deleted (right) in GIACs compared with in non-GIACs.
(C) DNA hypermethylation frequency (top), mutation density (middle), and arm-level and focal copy-number events (bottom) in GIACs and non-GIACs.
(D) Percent GOF or LOF events in developmental transcription factors by cancer type. See also Figure S1 and Tables S1–S6.Dienstmann et al., 2017; Guinney et al., 2015; Roepman et al.,
2014; Tan et al., 2011). We found that unsupervised clustering
of GIACs using mRNA, miRNA, and RPPA data was strongly
influenced by tissue type, thus complicating defining molecular
groups spanning anatomic boundaries. By contrast, evaluation
of mutations, copy-number alterations, and DNA methylation
patterns yielded tumor subtypes spanning tissue boundaries
(Figure S1A). Our subgroups are consistent with those identified
by recent genomic research across GIACs (Cancer Genome
Atlas Research Network, 2012, 2014, 2017; Cristescu et al.,
2015; Secrier et al., 2016; Wang et al., 2014), and rely on molec-
ular features generally evaluable by the clinical community.
A subgroup of tumors was characterized by a high Epstein-
Barr virus (EBV) burden, as previously determined via mRNA
and miRNA analysis (Cancer Genome Atlas Research Network,
2014) (Figure 2A). EBV+ tumors, found only in the stomach
(n = 30), display the most extensive hypermethylation of any
tumor type in TCGA (see Figure S4.6 in Cancer Genome Atlas
Research Network, 2014). Hypermutated tumors (n = 157),
defined by mutation density >10 per megabase (Mb) (Fig-ure S2A) were further substratified based on the implied
mechanism of replication error. MSI, arising from defective
DNA mismatch repair, often yields insertion-deletion (indel)
mutations in addition to single-nucleotide variants (SNVs) (Sia
et al., 1997), whereas hotspot mutations in polymerase epsilon
(POLE) are associated with SNV-predominant profiles (Cancer
Genome Atlas Research Network, 2012; Palles et al., 2013;
Zhou et al., 2009) (Figure 2B). Hypermutated samples with an
indel density of >1 per Mb and an indel/SNV ratio >1/150 con-
sisted of essentially all tumors with clinically defined MSI (MSI,
n = 138; 54% gastroesophageal or GE; 46% colorectal or CR)
(Figure S2B). All other hypermutated samples were categorized
as hypermutated-SNV (HM-SNV), (n = 19 [n = 11 with
POLE mutations]; 47% GE; 53% CR) (Figure 2B and S2B).
The remaining two groups were distinguished by presence or
absence of extensive SCNAs (Figure S2C). Chromosomal insta-
bility (CIN) tumors (n = 625, 48% GE; 52% CR) exhibited
marked aneuploidy, defined by a clonal deletion score (CDS),
(see STAR Methods) > 0.0249, which is largely determined
by chromosome- and arm-level losses. By contrast, genomeCancer Cell 33, 721–735, April 9, 2018 723
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Figure 2. Molecular Subtypes of GIACs
(A) Flowchart of molecular subtypes: Epstein-Barr virus (EBV)-positive (red); hypermutated-single-nucleotide variant predominant (HM-SNV) (gold); microsatellite
instability (MSI) (blue); chromosomal instability (CIN) (purple); and genomically stable (GS) (green).
(B) 3D plot of GIACs by SNV density, indel density, and clonal deletion score (CDS). Tumors annotated as upper GI (crosses) and lower GI (circles) and color coded
by subtypes.
(C) IFN-g pathway score (top) and CD8+ T cell score (adjusted for total leukocytes; bottom) by subtypes stratified by upper versus lower GI. Horizontal bars
indicate median values, boxes represent interquartile range, and whiskers indicate values within 1.5 times interquartile range.
(D) Unsupervised analysis of DNA methylation across GIACs.
(E and F) Distribution of subtypes (E) and CIMP subgroups (F) across anatomic regions.
(G and H) Distribution of MLH1/CDKN2A silencing (G) and subtypes (H) in CIMP-H tumors by anatomic region. See also Figure S2.stable (GS) (n = 109, 47% GE; 53% CR) samples lacked such
aneuploidy (Figures 2B and S2B).
We evaluated the relationship between our molecular sub-
types and consensus molecular subtypes (CMSs), which have
been established for CRC based primarily on gene expression
(Guinney et al., 2015). We applied the CMS classification system
to the lower GI tumors in our study and found a significant asso-
ciation between the two groupings (p < 2.2 3 1016), but with
noteworthy differences (Figure S2D). The CMS1-MSI immune
grouping did not discriminate MSI tumors from the HM-SNV
tumors (Figure S2B). A substantial fraction of GSCRCswere rep-
resented in the CMS3-metabolic subtype (p = 1.6 3 106), but
the CMS system appeared to be largely unable to distinguish
CIN and GS (Figure S2D).
Our molecular groupings also correlated with key immune fea-
tures of GIACs (Thorsson et al., 2018) (Figures 2C and S2E). As
previously reported, EBV+ tumors possessed the highest gene
expression scores for CD8+ T cells, M1-macrophages, and inter-
feron-g (IFN-g) signatures (Figures 2C and S2E) (Derks et al.,
2016; Koh et al., 2017). MSI tumors showed the next greatest
IFN-g signature, consistent with reported immunogenicity of724 Cancer Cell 33, 721–735, April 9, 2018MSI tumors (Le et al., 2017). Moreover, MSI tumors displayed
diverse immune signatures depending on their tissue of origin
(Figures S2F and S2G); for example, checkpoint protein CD276
was significantly enriched in MSI CRC, whereas ENTPD1 was
preferentially expressed in MSI gastroesophageal adenocarci-
nomas (GEAs) (Figure S2G). HM-SNV also demonstrated hetero-
geneity in immune signature expression when comparing the
upper and lowerGI tract (FigureS2F).Of translational importance,
an attenuation in HLA/antigen presentation (Figure S2F) and sig-
nificant elevation in natural killer (NK) cell gene expression was
found in HM-SNV CRC (Figure S2H), suggesting that NK cells
are found in a subset of tumors and are capable of anti-tumor
responses (Wagner et al., 2017). The cytotoxic activity of NK cells
is finely regulated by the integration of activating and inhibitor
cues (Ljunggren and Malmberg, 2007), and cells lacking MHC
expression often are subjected to NK cell cytotoxicity due to the
absence of inhibitory cues mediated by killer cell immunoglob-
ulin-like receptor. These data suggest agents to enhance NK
activity may be a therapeutic option for HM-SNV tumors.
Unsupervised clustering of DNA methylation data across
GIACs using cancer-associated methylated sites (excluding
A B
C D E
Figure 3. Analysis of MSI and CIMP Tumors
(A) Methylation subtypes with four CIMPs: EBV-CIMP (red), CIMP-high (blue), GEA-CIMP low (yellow), and CRC-CIMP low (green) with alterations of indi-
cated genes.
(B) Methylation profiles of union of CIMP-high and MSI tumors with MLH1 silencing, KRAS, BRAF, MLH1, and MSH2 mutations.
(C) Features of MSI tumors stratified by upper versus lower GI and by CIMP-high status. Horizontal bars indicate median values, boxes represent interquartile
range, and whiskers indicate values within 1.5 times interquartile range.
(D) Unique and overlapping epigenetically silenced genes (>25%) in upper GI (top left), upper GI tumors excluding EBV+ (top right), lower GI (bottom, left), andMSI
(bottom, right).
(E) Frequency of silencing (black) andmutation (blue) of select genes in upper GIMSI (vertical axis) versus lower GIMSI tumors (horizontal axis). See also Figure S3
and Table S7.CpGs with tissue-specific methylation) revealed extensive CpG
island methylation in the EBV+ gastric cancers, distinguishing
these tumors (Figure 2D), as previously noted by us and others
(Cancer Genome Atlas Research Network, 2014; Matsusaka
et al., 2011; Wang et al., 2014). The remaining tumors could be
characterized as those lacking a CIMP (non-CIMP) and those
displaying a low or high frequency of DNA hypermethylation
(CIMP-L and CIMP-H, respectively).
Hypermutated tumors were located primarily in the central
part of the GI tract, the distal stomach, and proximal colon,
whereas CIN tumors were more prevalent in the anatomic ex-
tremes, the esophagus and distal colon/rectum (Figure 2E) (Bu-
dinska et al., 2013). Although CIMP-H occurred throughout the
upper GI tract and proximal colon (Figure 2F), epigenetic
silencing of MLH1, responsible for MSI, was observed primarily
in the distal stomach and proximal colon (Figure 2G). Within
the proximal stomach and esophagus, only 4/29 (14%) of
CIMP-H tumors exhibited MLH1 epigenetic silencing and MSI,
while 23 of the 29 (79%) were microsatellite stable (MSS) anddisplayed the CIN phenotype (Figure 2H). In the lower GI tract,
CIMP-H and MSI were largely absent in the descending colon
and rectum (Figures 2E and 2H).
Analysis of Hypermethylation and Hypermutation
MSI tumors exhibited distinct expression features independent
of tissue of origin, implying common biological features of this
class of tumors (Figures S3A and S3B). Most sporadicMSI cases
in both colorectal and gastric cancer arise as a consequence of
epigenetic silencing of MLH1 by promoter DNA hypermethyla-
tion (Herman et al., 1998; Leung et al., 1999) in the context of
CIMP-H (Weisenberger et al., 2006). MSI tumors with MLH1
methylation were associated with BRAFV600E mutation only in
the colon, not the stomach (Figure 3A). KRAS mutations were
found primarily in CIMP-L tumors of the lower GI tract, whereas
KRAS amplificationwas observed in upperGI tumors (Figure 3A).
TFAP2E promoter methylation, which is associated with non-
response to chemotherapy in CRC (Ebert et al., 2012), was found
in a substantial fraction of CIMP-H tumors and in almost all EBV+Cancer Cell 33, 721–735, April 9, 2018 725
gastric cancers (Figure 3A). CIMP-H tumors showed near-ubiq-
uitous methylation of the tumor suppressor CDKN2A in gastric
and colon MSI tumors (Figures 3A and 3B). However, 39% of
the CIMP-H tumors lackedMLH1 silencing andMSI, and instead
included other classes of GIACs, most commonly CIN tumors in
the proximal stomach/esophagus or rectum/descending colon
(Figures 2H and 3B).
Given the tight associations between CIMP-H and MSI and
their heterogeneity across anatomic boundaries, we studied
the collection of tumors containing either of these features in
more detail (Figure 3B). A portion of MSI cases lacking both
MLH1 methylation and the CIMP contained somatic mutations
in MLH1 or MSH2, indicating an alternative route to loss of
DNA mismatch repair (Figure 3B, right side). These tumors
were preferentially associated with mutations in KRAS rather
than BRAF. A small number of MSI tumors (n = 8) could not be
explained by genetic or epigenetic inactivation of a mismatch
repair gene.
Broadly, the MSI group of CRCs harbored lower WNT signa-
tures than did other CRCs (Figures S3C and S3D), a finding
that may be attributable to a reduced reliance of CIMP-H tumors
onWNT signaling. AmongMSI CRCs, those arising in the context
of CIMP-H have a lower percentage of APCmutation (28%) than
those arising in either CIMP-L (78%) or non-CIMP (58%) (Fisher’s
exact test p = 0.0091). This finding holds true for MSS CIMP-H
tumors as well, and is discussed in the GS subtype section
below. CIMP-H MSI CRC showed a reduced combined fre-
quency of either APC or CTNNB1 mutations and decreased
WNT gene expression signatures compared with non-CIMP-H
MSI cases, andweremore similar to upper GI MSI tumors in their
lower reliance on WNT activation (Figure 3C). Despite the
reduced frequency of APC and CTNNB1 mutations, MSI
CIMP-H tumors displayed overall greater mutational densities
and arose at an older age of onset than did non-CIMP-H MSI
cases or upper GI MSI cases (Figure 3C).
We investigated the genes silenced by promoter hypermethy-
lation in the molecular subgroups (Figures 3D and 3E; Table S7).
Pathway analysis of epigenetically silenced genes among all
subgroups revealed enrichment for genes encoding DNA bind-
ing proteins and transcription factors, consistent with previous
findings of enrichment for stem cell polycomb target genes
(Widschwendter et al., 2007). We identified 135 genes silenced
in at least 25% of the upper or lower GI MSI tumors and
compared their relative frequency of silencing and frequency of
several key gene mutations (Figure 3E). HUNK, a negative regu-
lator of intestinal cell proliferation (Reed et al., 2015), was found
to be frequently silenced in MSI tumors. Another frequently
silenced gene, ELOVL5, lies within the locus with germline vari-
ants most significantly linked to survival of CRC patients (Phipps
et al., 2016).
Molecular Features of the CIN Subtype
The landscape of SCNAs revealed a more finely fragmented
genome in GEA compared with CRC, despite an overall similar
pattern of affected regions of the genome (Figure 4A). Evaluation
of SCNA distribution, categorized by both focality and intensity,
revealed higher prevalence of focal copy-number events within
the CINGEA population (Figures 4B and S4A). The difference be-
tween the upper and lower GI was greater for focal amplifications726 Cancer Cell 33, 721–735, April 9, 2018than for deletions (Figure 4B), primarily evident in high-amplitude
focal amplifications (Figure S4A). We developed a score that
captures the quantity and intensity of focal high-level amplicons
(see STARMethods). CIN tumors with a higher score were desig-
nated CIN-Focal (CIN-F), whereas those with a lower score, and
therefore low-amplitude, broader amplicons, were called CIN-
Broad (CIN-B) (Figure 4C). The distribution of these two classes
of CIN differed between upper and lower GIACs, with CIN GEAs
displaying 74% CIN-F and 26% CIN-B, and CRCs showing
reversed proportions consisting of 22% CIN-F and 78% CIN-B
(Figure 4C). Despite this difference between upper and lower
GI tumors, the ratios of CIN-B/CIN-F did not vary anatomically
within upper GI tumors or within the lower GI tract tumors (Fig-
ure S4B). Notably, in addition to the higher prevalence of
CIN-F in upper GIACs, such CIN-F GEAs displayed a higher
intensity in the focal-amplification score compared with their
CIN-F CRC counterparts (Figure S4C). CIN-F GEA was associ-
ated with advanced tumor stage, underscoring its potential
clinical significance (Figure 4D).
Although CIMP frequency displayed an anatomic gradient
within the upper GI (Figure S4D), we found no correlation of
CIMP class with arm-level or focal SCNAs in CIN (Figure S4E).
CIN-F GEAs demonstrated significantly more whole-genome
duplication (WGD) than did CIN-B GEAs, 68% versus 42% (Fig-
ures 4E and S4F), with evidence of two or more genome dou-
blings (WGD2) in 18% of CIN-F compared with 7% of CIN-B in
upper GI CIN tumors. WGD2 was associated with poor survival
in GEA, independent of age and stage (Figure S4G). However,
the strong association of genomic doubling and CIN-F was not
observed in CRC, despite similar total rates of genome duplica-
tion (Figure S4H; 59% in lower GI and 61% in the upper GI).
CIN-F GEAs sustained significantly more frequent focal ampli-
fication of genes encoding receptor tyrosine kinases, KRAS
and cell-cycle mediators (Figure 4F). In contrast, CIN-B GEAs
more commonly sustained activating mutations of oncogenes
(e.g., KRAS and ERBB2) than did GEA-CIN-F tumors (Figure 4F).
ERBB2 amplifications significantly co-occurred with CCNE1
amplifications (p = 0.039) and trended toward co-occurrence
with gains in chr.20q/SRC (p = 0.0692). Intriguingly, activating
mutations in ERBB2 co-occurred with ERBB2 amplifications
(p = 0.0087). CIN-B GEAs harbored more frequent somatic inac-
tivation of tumor suppressors related to cell-cycle regulation
(e.g., CDKN2A), WNT pathway activation (e.g., APC), and trans-
forming growth factor b (TGF-b) regulation (e.g., SMAD2 and
SMAD4) than CIN GEA-F. By contrast, CIN-F GEA showed a
higher frequency of TP53 mutations (Figure 4F; 76% versus
54%) and higher rates of oncogene amplifications (Figure 4G).
Among lower GI CIN tumors, the differences in somatic muta-
tions and copy-number alterations found in CIN-F and CIN-B tu-
mors were modest (Figure S4I), although CIN-F did associate
with poorer survival in CRC (Cox regression p = 0.0053, adjusted
for stage, age, and molecular subtype). We identified amplifica-
tions including CDX2, ERBB2, and CCND2 enriched in these
tumors. Consistent with the different patterns of CIN between
upper and lower GI cancers, we found that ERBB2+ CRC not
only harbor lower CIN-F scores (Figure S4J), but also fewer co-
occurring genomic alterations than ERBB2+ GEA (Figure S4K).
These findings are consistent with efficacy in CRC of ERBB2
therapy without chemotherapy (Sartore-Bianchi et al., 2016),
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Figure 4. Molecular Features of the CIN Subtype in Upper GI
(A) Copy-number heatmap of non-hypermutated GIACs with amplification (red) and deletion (blue) with upper GI CIN tumors (top), CIN CRC (middle), and GS
(bottom).
(B) Plots of arm-level and focal copy-number events in CIN tumors by the upper and lower GI tract. Horizontal bars indicate median values, boxes represent
interquartile range, and whiskers indicate values within 1.5 times interquartile range.
(C) Distribution of CIN-F (CIN-Focal) score by upper and lower GI CIN tumors. CIN-B denotes CIN-Broad.
(D) Distribution of CIN-F score by clinical stage in the upper GI. Horizontal bars indicate median values, boxes represent interquartile range, and whiskers indicate
values within 1.5 times interquartile range.
(E) Whole-genome doubling (WGD) in CIN-F and CIN-B tumors in the upper GI tract; WGD1 indicates one WGD, and WGD2 indicates > one WGD.
(F) Frequency of distinct classes of somatic alterations in RAS and receptor tyrosine kinases (RTK)(KRAS, PIK3CA, BRAF, ERBB3, ERBB2, NRAS, EGFR, FGFR1,
and FGFR2), cell-cycle (CC; FBXW7, CCNE1, CDK6, CDKN2A, CDKN1B, CCND1, andCCND2), and tumor suppressor genes (TSG) includingWNT (APC, RNF43,
SOX9, TCF7L2, and CTNNB1), TGF-b: TGFBR2, ACVR2A, ACVR1B, SMAD4, SMAD2, and SMAD), and TP53 in upper GI CIN-F and CIN-B tumors.
(G) Schematic model of CIN-F and CIN-B pathogenesis in the upper GI. See also Figure S4.compared with ERBB2+ GEA, which often carry co-occurring
amplified oncogenes implicated in de novo resistance (Janjigian
et al., 2018; Kim et al., 2014).
CIN-B andCIN-FCRCdisplayed comparable rates ofAPC and
KRASmutations (Figure S4I;APC: 79%versus 87%;KRAS: 35%
versus 44%). However, PIK3CA mutations and TGF-b pathway
alterations were more common in CIN-B CRC than in CIN-F
CRC (Figure S4I). Both groups of CINCRCshad somatic patterns
more closely resembling the CIN-B GEA group, in which onco-
geneswere activatedmorecommonly bymutation thanbyampli-
fication. Thesedata suggest that thepreponderanceof earlyAPC
loss and selection for mutational activation of oncogenes like
KRAS may precede a form of aneuploidy and transformation
distinct from the catastrophic aneuploidy and resulting oncogene
amplification occurring in GEA (Figure 4G).
Among CIN CRCs, we observed more frequent CIMP, primar-
ily CIMP-L, in proximal, right-sided CIN tumors and less frequent
CIMP in distal, left-sided ones (Figure S5A). Arm-level SCNAs
were significantly less frequent in CIMP+ CIN CRCs (Wilcoxon
p = 2.7 3 109), despite the lack of an overall difference in focalalterations (Figure S5B). Among chromosome arms, gain of 20q
was most enriched in non-CIMP CIN CRC, with a mean copy-
number gain of 1.8 (ploidy-adjusted), compared with 1.1 in
CIMP+ CIN CRC (Figure S5C). By contrast, except for TP53,
which was more frequently mutated in non-CIMP CIN tumors,
the frequency of somatic mutations was significantly higher in
CIMP+ CIN CRC (Figure S5D), notably affecting the TGF-b
pathway and key oncogenes including KRAS/NRAS/BRAF and
PIK3CA. Dichotomizing CIN CRC tumors by CIMP status thus
showed parallels to the division of upper GI CIN tumors by
CIN-F/CIN-B status. CIMP+ CIN CRC, like CIN-B GEA, harbored
more oncogene mutations (Figure 5A). Taken together, these
data suggest that CIMP status may play an important role in
shaping evolution of CIN tumors in the lower GI tract, and to a
lesser extent in the upper GI tract.
Molecular Features of the GS Subtype
Although CRCs are classically divided between hypermutated/
MSI and CIN (Bijlsma et al., 2017), we detected a population of
CRCs lacking both aneuploidy/CIN and hypermutation, a groupCancer Cell 33, 721–735, April 9, 2018 727
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Figure 5. Molecular Features of CIN and GS Colorectal Cancer
(A) Frequency of somatic alterations in indicated genes or pathways in non-CIMP CIN, CIMP-H/L CIN, and GS lower GI tumors.
(B) SCNAs (top), mutation density (middle), and CIMP classes (bottom) across subtypes in the lower GI tract. Horizontal bars indicate median values, boxes
represent interquartile range, and whiskers indicate values within 1.5 times interquartile range.
(C) Distribution of somatic mutations in SOX9 and PCBP1 in lower GI GS.
(D) Schematic model of pathogenesis of molecular subtypes in lower GI.
(E) Frequency of mutations in indicated genes in lower GI CIN/GS stratified anatomically. See also Figure S5.we classified as GS (Figure 5B). Unlike with MSI, these GS CRCs
shared few underlying biologic features with GS in upper GIACs.
As we reported previously (Cancer Genome Atlas Research
Network, 2014), upper GI GS tumors are enriched for the
diffuse-type gastric cancer (65.7%) and commonly harbor muta-
tions in CDH1 and RHOA (Figure S5E). Thus, upper GI GS, such
as EBV+ tumors, represent an essentially unique entity confined
to the stomach.
GS CRCs shared features of other CRCs; like the CIN CRCs,
GS CRCs shared a predilection for loss of APC (GS 81%
versus CIN 85%, Figure S5F). GS CRCs were more common in
ascending and transverse colon (Figure 2E) and when compared
with the CIN CRCs, showed significant enrichment for the
CIMP-L phenotype (79% versus 40%, p = 1.23 109, Figure 5B)
and for theCMS3metabolic subtype (p = 1.63 106, Figure S2D)
(Guinney et al., 2015). Despite having fewer SCNAs, a subset of
GS CRCs showed amplifications of IGF2 (q < 0.05) (Figure S5G).
Mitogen-activated protein kinase pathway mutations were more
common in these tumors, withKRAS, NRAS, orBRAFmutated in
69%, 10%, and 9% of tumors, respectively, and with PIK3CA
mutations present in 43%,comparedwith 22%ofCINCRCs (Fig-
ure 5A). Consistent with the relative lack of aneuploidy, TP53
mutations were less common (16%) in GS compared with CIN
tumors (80%) (Figure S5E). However, we observed enrichment728 Cancer Cell 33, 721–735, April 9, 2018for somatic mutations in SOX9, which encodes a transcription
factor, and in PCBP1, which encodes an RNA-binding protein
that regulates splicing, mRNA stability, and translation (Leffers
et al., 1995) (Figures 5A, 5C, and S5H). SOX9, mutated in 29%
of GS CRCs, encodes a WNT-regulated transcription factor
that controls cell fate andcrypt homeostasis in intestinal develop-
ment (McConnell et al., 2011; Nandan et al., 2014). GSCRCswith
mutations in SOX9 also had more frequent somatic mutations in
the TGF-bpathwaygenes, includingPCBP1 (FigureS5I).Ourmu-
tation analysis within GS revealed highly clusteredmissensemu-
tations in the KH domain of PCBP1 in 13% of GS CRCs, raising
the potential for a GOF event (Figure 5C). Interestingly, overex-
pression of wild-type PCBP1 was associated with oxaliplatin
resistance in CRC (Guo et al., 2010).
Overall, GS CRCs had more frequent mutations in the TGF-b
pathway, RAS/RAF genes, and PIK3CA than did CIN CRCs (Fig-
ure S5F). Comparison of GS CRCs with CIN CRCs revealed a
progressive gradation of features between non-CIMP CIN
CRCs, CIMP-H or CIMP-L CIN CRCs, and GS CRCs (Figure 5A).
These data suggest a pathway to cancer in the colorectum in
which APC mutant cells, typically containing the CIMP-L pheno-
type, are able to undergo transformation by sustaining additional
pathogenic mutations without the need for p53 loss or aneu-
ploidy (Figure 5D).
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Figure 6. Gastrointestinal Adenocarcinoma Mutational Signatures
(A) Mutation signatures in non-hypermutated GIACs displayed by substitution class and sequence immediately 30 and 50 to the mutated base.
(B) Key molecular features of GIACs by anatomical distribution.
(C) Intensities of mutational signatures in CIN and GS subtypes by the upper and lower GI.
(D) BRCA signature in CIN and GS tumors in the upper and lower GI tract.
(E) AA > AC signature stratified by CIN-F and CIN-B (top) and TP53 mutation (bottom) in upper GI CIN tumors.
(F) CpG > TpG signature in CIN and GS tumors in the upper and lower GI stratified by CIMP status. For all boxplots, horizontal bars indicate median values, boxes
represent interquartile range, and whiskers indicate values within 1.5 times interquartile range. See also Figure S6.We had noted earlier that CIMP-H MSI tumors appeared to
rely less on WNT signaling. CIMP-H MSS tumors also displayed
reduced rates of APC mutation (47%) compared with CIMP-L
(87%) or non-CIMP (86%) (Fisher’s exact test p = 0.00066).
These findings suggest an alternative CRC pathway that is not
initiated by mutation of APC, but rather by an epigenetic aberra-
tion causing CIMP-H. If MLH1 is silenced in the context of
CIMP-H, then the tumor would become MSI, whereas, if MLH1
is not affected, the tumor would develop along the CIN pathway
to give rise to CIMP-H MSS CIN tumors (Figure 5D). Non-hyper-
mutated CRCs from the right-sided (ascending/transverse)
colon revealed significantly higher rates of KRAS, PIK3CA, and
SOX9 mutation than those from the left-sided (descending)
colon/rectum (Figure 5E).
Mutational Signatures in GIACs
MSI and POLE signatures dominated the total mutational signa-
ture scores among GIACs as a consequence of the high muta-
tional burden in MSI and POLE-deficient tumors (Figures S6Aand S6B). Signature discovery following removal of hypermu-
tated cases revealed a BRCA signature (COSMIC signature 3),
two APOBEC signatures, a signature resembling COSMIC signa-
ture 17 with common AA > AC transversions, and a signature
dominated by C > T transitions at CpG dinucleotides (COSMIC
signature 1) (Figures 6A–6F) (Alexandrov et al., 2013; Bignell
et al., 2010). The APOBEC signatures contributed minimally to
the mutational profile across GIACs (Figures 6B, 6C, and S6C),
but the other three signatures had substantial activity in non-hy-
permutated GIACs with the AA > AC signature limited to upper
GIACs (Figures 6B, 6C, 6E, and S6D). A recent study identified
the existence of the BRCA signature in gastric cancers that
lacked mutations in BRCA1 and BRCA2 (Alexandrov et al.,
2015). We confirmed the presence of BRCA signature activity
in GIACs, with significant enrichment of somatic and germline
mutations in several homologous recombination genes such as
BRCA1, BRCA2, andPALB2 (Figure S6E). BRCA signature activ-
ity was also significantly enriched in tumors with epigenetic
silencing of BRCA1 or RAD51C, especially within EBV+ GCsCancer Cell 33, 721–735, April 9, 2018 729
Figure 7. Integrated Molecular Comparison of Somatic Alterations across GIAC Molecular Subtypes
(A–C) Alterations in select genes and pathways including RTK/RAS/PI3-K (A), TP53, cell cycle (B), and WNT/TGF-b (C). Deep deletions representing loss of
more than half of the gene copies for the given ploidy of the tumor, blue; amplifications, red; missense mutations in the COSMIC repository, green; nonsense
or frameshift mutations, black. Percentage of somatic alteration is indicated by numbers to the left of each gene box and divided by the upper (U) and
lower GI (L).(Figure S6F). We observed a significant association between
BRCA signature activity and upper GI cancers, particularly the
CIN subtype (Figure 6D). The BRCA signature was associated
only with focal SCNA events (Figure S6G), which are likely initi-
ated by double-strand breaks. The AA > AC signature was also
enriched in upper-GI CIN (Figures 6E, S6C, and S6D), most
notably in the tubular esophagus (Figure S6D). Moreover, this
mutational signature was enriched in CIN-F and TP53-mutated
upper GI CIN tumors (Figure 6E). The AA > AC signature lacks
a known etiology, but its association with GEA and its correlation
with higher CIN-F scores raises the possibility that this signature
reflects a process that contributes to greater focal aneuploidy
observed in GEAs comparedwith CRCs and differences in onco-
gene profiles between upper and lower GIACs (Figure 7).
The CpG > TpG pattern, often termed the ‘‘aging signature’’,
was the most common signature among all tumors, but it was
especially frequent in right-sided CRC (Figure S6C). This signa-
ture is thought to arise from spontaneous hydrolytic deamination
of 5-methylcytosine, and is consolidated as a persistent muta-
tion if it occurs during DNA replication. Hence, this signature
tracks the cumulative number of cell divisions and aging.
Although we observed an association with CIMP status (Fig-
ure 6F), we do not believe that this is explained by a simple quan-730 Cancer Cell 33, 721–735, April 9, 2018titative difference in DNA methylation. The CIMP hypermethyla-
tion is measured primarily at promoter CpG islands, which are
unmethylated in normal cells and thus do not sustain many
CpG > TpG mutations prior to acquisition of methylation and
clonal expansion, whereas the mutation signatures were ob-
tained by exome sequencing of gene bodies, which are generally
highly methylated. The association between CIMP status and
CpG > TpG signature may reflect the fact that CIMP tumors
require more cell divisions to progress and thus acquire more
CpG > TpG mutations over time.
DISCUSSION
GIACs originate from columnar epithelium with a shared endo-
dermal origin and display a spectrum of common molecular fea-
tures, such as aneuploidy andMSI, which span anatomic bound-
aries. GIACs are enriched for activation of the WNT signaling
pathway, particularly in the lower GI tract, consistent with the
importance of WNT in GI development (Schepers and Clevers,
2012). We found that CIMP-H CRC appeared less dependent
on canonical WNT signaling mutations and pathways. GIACs
also displayed a predisposition for disruptions in TGF-b and
SMAD signaling components. TGF-b signaling helps to maintain
intestinal stem cell equilibrium, promoting growth during devel-
opment, but controlling self-renewal in adult epithelium (Mishra
et al., 2005).
The vast majority of sporadic MSI tumors arise as a conse-
quence of promoter methylation of MLH1 in the context of
CIMP-H. Methylation profiles of CIMP-H tumors are quite
consistent throughout the GI tract. However, MLH1 silencing
within CIMP-H is much more anatomically restricted, primarily
observed in the distal stomach and proximal (ascending and
transverse) colon, but notably uncommon in proximal upper
GI cancers. The epithelia of the distal stomach and proximal
colon appear more susceptible to oncogenic effects of MLH1
silencing. High rates of epithelial cell turnover with accompa-
nying DNA replication may more effectively consolidate replica-
tion-associated errors in these sections of the GI tract. This
hypothesis is consistent with the tumor spectrum observed
with germline mutations in mismatch repair genes, leading to
increased risk of cancers arising in highly proliferative tissues
(Lynch et al., 2015). In this scenario, stochastic promoter
methylation of MLH1 from CIMP-H would provide less selective
advantage when arising in the less proliferative sections of the
GI tract.
CIMP-H GIACs possessed other differences in molecular fea-
tures between various anatomic locations. BRAFV600Emutations
occurred almost exclusively in CIMP-H tumors of the ascending
colon and were absent from otherwise similar CIMP-H GEAs. In
addition, some colorectal CIMP-H tumors with similar DNA
methylation profiles lacked BRAFV600E mutations, a finding
inconsistent with the proposed role for BRAFV600E mutation as
a cause of CIMP-H (Fang et al., 2016). Alternatively, CIMP may
provide a permissive environment for BRAFV600E mutation,
perhaps by silencing pathways involved in oncogene-induced
senescence and apoptosis (Hinoue et al., 2009). Despite the
large overlap of CIMP-H and MSI in GIACs, our data revealed
that this co-occurrence occurs predominantly in the distal stom-
ach and ascending colon. The etiology for CIMP-H tumors
commonly progressing via a CIN pathway in proximal GE and
distal CRC is not established.
CIN is a common feature of GIACs and other tumors (Cancer
Genome Atlas Research Network, 2012; 2014, 2017; Hoadley
et al., 2014). Despite the deleterious effect on cellular and organ-
ismal fitness (Sheltzer et al., 2011, 2017; Torres et al., 2007; Wil-
liams et al., 2008), CIN with its resultant aneuploidy remains the
predominant molecular subtype among GIACs, found most
frequently in the proximal upper and distal lower GI tract (Dulak
et al., 2012). Unlike tumors with MSI, CIN tumors had more
discrepant molecular features between upper and lower GI
cancers. Most striking was the preponderance of focal, high-
amplitude SCNAs, especially amplifications, in GEAs. Within
CIN GEAs, we found that tumors with high CIN-F scores had a
strong association with prior genome doubling, a process
associated with CIN (Ganem et al., 2007). Amplifications in
CIN-F GEAs commonly targeted mitogen pathway components,
cell-cycle regulators, and lineage survival transcription factors,
whereas CIN-B and GS tumors more frequently carried acti-
vating mutations in these pathways.
A notable finding was the predilection in CIN-B GEAs for
alterations in tumor suppressors such as CDKN2A, APC, and
SMAD4. These findings suggest that the marked aneuploidyfound within the CIN-F GEAs is less apt to occur in precursors
with pathogenic alterations other than TP53. One explanation is
that precursors with altered oncogenes/tumor suppressors
other than TP53 have less requirement for more ‘‘catastrophic’’
aneuploidy to simultaneously abrogate multiple such check-
points. By contrast, such marked instability could facilitate
transformation in precursors with p53 loss without as many
other preexisting pathogenic alterations. Indeed, although p53
loss alone is not sufficient to promote aneuploidy (Bunz et al.,
2002), several lines of evidence support its necessity, most
likely by circumventing p53-dependent cell-cycle arrest in
response to damage by reactive oxygen species (Guo et al.,
2010), to mutations in ataxia telangiectasia (Li et al., 2010), or
to spindle assembly checkpoint activation (Thompson and
Compton, 2010). Given these data, the lesser rates of CIN-F
in lower GI CIN tumors (compared with CIN tumors of the upper
GI tract) may be a consequence of APC loss as an early event
in colorectal neoplasia, leading to mutations in TP53 rarely
occurring in the absence of a prior APC loss. Instead, we noted
that CIMP status likely has a stronger influence on the features
of CIN CRC, with CIMP being associated with mutations in
KRAS and in tumor suppressor pathways such as TGF-b.
Aneuploid CIMP tumors in the lower GI tract showed lower
rates of SCNA, but a greater number of oncogenic mutations
compared with non-CIMP. Both upper and lower GI CIN tumors
were also associated with the BRCA mutational signature.
However, the propensity for greater CIN-F in upper GIACs
correlated with the AA > AC mutational signature, a signature
of unknown etiology, previously reported in upper GI tumors
(Dulak et al., 2013).
Our exploration of the role of CIMP in shaping the features of
CIN in CRC became linked with our finding of a GS CRC subtype
falling outside the classic CIN/MSI CRCdichotomy. This GS sub-
typemay partially overlapwith the previously identifiedmicrosat-
ellite and chromosome stable (MACS) CRCs (Chan et al., 2001),
while showing important differences. TheMACS phenotype is an
independent predictor of poor outcome (Banerjea et al., 2009), in
contrast, GS CRCs are enriched for earlier stage tumors. MACS
tumors have an elevated proportion of early onset cases (Chan
et al., 2001), whereas GS CRCs have a higher mean age at diag-
nosis than CIN cases. Like MACS, HM-SNV cases are microsat-
ellite and genome stable, and also arise in younger patients, so it
is possible that some early-onset MACS tumors may have repre-
sented unrecognized HM-SNV tumors. The GS CRCs overlap
with a subgroup identified by gene expression clustering as
CMS3 (Guinney et al., 2015) and commonly displaying CIMP-L.
Many features enriched in CIMP CIN CRCs compared with
non-CIMP CIN CRCs were even more prevalent in GS CRCs.
Moreover, we found these tumors to have recurrent mutations
in SOX9 and PCBP1. While the presence of frameshift mutations
of SOX9 implies LOF, truncating mutations in SOX9 are overex-
pressed in primary tumor specimens (Javier et al., 2016), making
their functional significance unclear. GS CRCs with mutations
in SOX9 also had more frequent somatic mutations in TGF-b
pathway genes, including PCBP1, which impacts TGF-b
signaling by regulating Smad3-associated alternative splicing
(Tripathi et al., 2016). Given the strikingly low frequency of
TP53 mutations in GS CRCs, the presence of SOX9 and
PCBP1mutations may co-operate with APC andKRASmutationCancer Cell 33, 721–735, April 9, 2018 731
to facilitate transformation, despite lack of hypermutation and
low levels of aneuploidy.
Our findings also bear some relevance to the evolving field of
immunotherapy, which already has established efficacy in MSI
tumors. The HM-SNV tumors, which display a large SNV burden
in the setting of POLE mutations, did not harbor the equivalent
CD8 or IFN-g signatures as did the MSI tumors, perhaps sug-
gesting that indel mutations may better generate neoantigens
than SNVs. The strong signatures in EBV+ tumors suggest
a potential for immune checkpoint inhibition in this subset.
The reason for consistently higher IFN-g signatures in upper GI
compared with lower GI adenocarcinomas when stratified by
molecular subtype is less obvious and may simply indicate that
GEAs are more immunogenic than CRC, results consistent
with the presence of clinical responses to PD1 inhibitor mono-
therapy in MSS GEAs, but not in CRCs (Jin and Yoon, 2016;
Muro et al., 2016).
In summary, these results highlight how processes such as
DNA hypermethylation and CIN can manifest themselves in
different ways across related tissues. In some instances, as
with DNA hypermethylation in upper-GI versus lower-GI MSI tu-
mors, such differences can be subtle. However, as the explora-
tion of CIN indicates, other processes can lead to substantially
different molecular outcomes across these regions. Provision
of greater detail in the various manifestations of molecular de-
fects may reveal new opportunities for targeted therapies for
these cancers. Furthermore, these data highlight how consider-
ation of molecular subtypes as well as organ of origin will be
essential in the study and treatment of cancer.STAR+METHODS
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Preparation kit
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Capture_Library_Preparation.pdf
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CONTACT FOR RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter W.
Laird (Peter.Laird@vai.org). Sequence data hosted at the GDC is under controlled access. Details for gaining access can be found at
(https://gdc.cancer.gov/access-data/data-access-processes-and-tools).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects and Tumor Data Selection
Molecular data were obtained as part of the Cancer Genome Atlas Project, from patients untreated by chemo- or radiation therapy
and who provided informed consent; tissue collection was approved by the local Institutional Review Boards (IRBs) as noted below.
GIAC cases (n=921) were selected as follows. Of the 559 Upper GI cases (171 ESCA and 388 STAD) in (Cancer Genome Atlas
Research Network, 2017), 90 were excluded as ESCC and two as undifferentiated (TCGA-2H-A9GQ, TCGA-VR-A8Q7). Of the re-
maining 467 Upper GI adenocarcinomas, 462 (79 ESCA, 383 STAD) cases have molecular data available from the five TCGA core
platforms (RNASeq, miRNASeq, DNA Methylation, SNP6, and mutation calls). We used germline DNA from blood or non-malignant
gastrointestinal tissue as a reference for detecting somatic alterations. For lower GI, all available TCGA COAD and READ cases were
considered, but cases bearing the BCR annotation ‘‘Redacted’’ were excluded, as were cases with Notification: ‘Unacceptable
Prior Treatment’ or ‘Item does not meet study protocol’. Review of COAD and READ pathology reports led to the exclusion of three
additional COAD cases from this study (TCGA-AA-A022: Pathology report indicates poorly-differentiated carcinoma of the neuroen-
docrine type; TCGA-AA-A02R: Pathology report shows poorly-differentiated carcinoma with positivity for both S-100 and chromog-
ranin, and focal synaptophysin; and TCGA-AZ-6607: Pathology report indicates this is likely to be a pancreaticobiliary primary tumor
metastasizing to colon. The remaining 459 lower GI cases (341 COAD and 118 READ) with molecular data available for the five plat-
forms were retained.
A group of 2,871 non-GIAC cases was constructed from TCGA tumor types BRCA, CESC, CHOL, LUAD, OV, PAAD, PRAD and
UCEC, comprising all cases meeting the established criteria of the PanCancer Atlas Consortium (exclusion of Redacted,‘Unaccept-
able Prior Treatment’ or ‘Item does not meet study protocol’ and cases with no molecular data). For BRCA, CHOL, PRAD, and OV,
and UCEC cases annotated as problematic by Expert Pathology Review (marked as AWG_excluded_because_of_pathology in the
PanCancerAtlas Merged Annotation File) were excluded. For CESC, LUAD, and PAAD, further exclusions were made based on case
review, as follows: CESC, retain only adenocarcinomas; LUAD, exclude samples without histology; PAAD, exclude samples with
cellularity < 20%.
Demographic data for patients are as follows: GIAC (60.3% male, median age 68 years, range 29-90 years); Non-GIAC (21.3%
male; median age 61 years, range 25 to 90 years).
TCGA Project Management collected necessary human subject documentation to ensure the project complies with 45-CFR-46
(the ‘‘Common Rule’’). The program has obtained documentation from every contributing clinical site to verify that IRB approval
has been obtained to participate in TCGA. Such documented approval may include one or more of the following:
d An IRB-approved protocol with Informed Consent specific to TCGA or a substantially similar program. In the latter case, if the
protocol was not TCGA-specific, the clinical site PI provided a further finding from the IRB that the already-approved protocol is
sufficient to participate in TCGA.
d A TCGA-specific IRB waiver has been granted.
d A TCGA-specific letter that the IRB considers one of the exemptions in 45-CFR-46 applicable. The two most common exemp-
tions cited were that the research falls under 46.102(f)(2) or 46.101(b)(4). Both exempt requirements for informed consent,
because the received data and material do not contain directly identifiable private information.
d A TCGA-specific letter that the IRB does not consider the use of these data and materials to be human subjects research. This
was most common for collections in which the donors were deceased.METHOD DETAILS
Sample Processing
RNA and DNA were extracted from tumor and adjacent normal tissue specimens using a modification of the DNA/RNA AllPrep kit
(Qiagen). The flow-through from the Qiagen DNA column was processed using a mirVana miRNA Isolation Kit (Ambion). This latter
step generated RNA preparations that included RNA <200 nt suitable for miRNA analysis. DNA was extracted from blood using the
QiaAmp blood midi kit (Qiagen). Each specimen was quantified bymeasuring Abs260 with a UV spectrophotometer or by PicoGreen
assay. DNA specimens were resolved by 1% agarose gel electrophoresis to confirm high molecular weight fragments. A custom
Sequenom SNP panel or the AmpFISTR Identifiler (Applied Biosystems) was utilized to verify tumor DNA and germline DNA were
derived from the same patient. Five hundred nanograms of each tumor and normal DNA were sent to Qiagen for REPLI-g whole
genome amplification using a 100 mg reaction scale. Only specimens yielding a minimum of 6.9 mg of tumor DNA, 5.15 mg RNA,Cancer Cell 33, 721–735.e1–e8, April 9, 2018 e2
and 4.9 mg of germline DNAwere included in this study. RNAwas analyzed via the RNA6000 Nano assay (Agilent) for determination of
an RNA Integrity Number (RIN), and only the cases with RIN >7.0 were included in this study.
Pathology Review
All samples were systematically evaluated by gastroenterological pathologists to confirm the histopathologic diagnosis and any
variant histology according to the most recent World Health Organization (WHO) classification(International Agency for Research
on Cancer, 2010). All tumor samples were assessed for tumor content (percent tumor nuclei), Tumor samples were evaluated for
the presence and extent of inflammatory infiltrate as well as the type of the infiltrating cells in the tumor microenvironment (lympho-
cytes, neutrophils, eosinophils, histiocytes, plasma cells). Any non-concordant diagnoses among the pathologists were re-reviewed
and resolution achieved after discussion.
DNA Sequencing Data
Exome capture was performed using Agilent SureSelect Human All Exon 50Mb according to themanufacturers’ instructions. Briefly,
0.5–3 micrograms of DNA from each sample were used to prepare the sequencing library through shearing of the DNA followed by
ligation of sequencing adaptors. All whole exome (WES) and whole genome (WGS) sequencing was performed on the Illumina HiSeq
platform. Paired-end sequencing (2 x 101 bp forWGS and 2 x 76 bp forWE) was carried out using HiSeq sequencing instruments; the
resulting data were analyzed with the current Illumina pipeline. Basic alignment and sequence QC were done with the Picard and
Firehose pipelines at the Broad Institute. Sequencing data were processed using two consecutive pipelines: (1) Sequencing
data processing pipeline (‘‘Picard pipeline’’). Picard (http://picard.sourceforge.net/) uses the reads and qualities produced by
the Illumina software for all lanes and libraries generated for a single sample (either tumor or normal) and produces a single BAM
file (http://samtools.sourceforge.net/SAM1.pdf) representing the sample. The final BAM file stores all reads and calibrated qualities
along with their alignments to the genome.
(2) Cancer genome analysis pipeline (‘‘Firehose pipeline’’). Firehose (http://www.broadinstitute.org/cancer/cga/Firehose)
takes the BAM files for the tumor and patient-matched normal samples and performs analyses including quality control, local realign-
ment, mutation calling, small insertion and deletion identification, rearrangement detection, coverage calculations and others as
described briefly below. The pipeline represents a set of tools for analyzing massively parallel sequencing data for both tumor
DNA samples and their patient-matched normal DNA samples. Firehose usesGenePattern (Reich et al., 2006) as its execution engine
for pipelines and modules based on input files specified by Firehose. The pipeline contains the following steps:
Quality Control
This step confirms identity of individual tumor and normal to avoid mix-ups between tumor and normal data for the same individual.
Local Realignment of Reads
This step realigns reads at sites that potentially harbor small insertions or deletions in either the tumor or the matched normal, to
decrease the number of false positive single nucleotide variations caused by misaligned reads.
Identification of Somatic Single Nucleotide Variations (SSNVs). This step detects candidate SSNVs using a statistical analysis of the
bases and qualities in the tumor and normal BAMs, using Mutect (Cibulskis et al., 2013).
Identification of Somatic Small Insertions and Deletions. In this step, putative somatic events were first identified within the tumor
BAM file and then filtered out using the corresponding normal data, using Indellocator (Ratan et al., 2015).
Mutation Data
A series of quality-control filters according to the MC3 MAF were applied to mutations: (1) A filter for artificial CC>CA mutations
caused by sample oxidation (8-oxoguanine) was applied to remove potential CC>CA artifacts (Costello et al., 2013); (2) Variants
that were frequently observed in the Exome Aggregation Consortium (http://exac.broadinstitute.org) were excluded; (3) mutations
with evidence of strand bias were excluded; (4) mutations with ‘‘ndp’’ labels were excluded; (5) duplicated mutations due to redun-
dant tumor or normal samples were excluded. Somatic mutation calling was focused on coding mutations spanning missense and
nonsense mutations, in-frame and frame-shift indels, and mutations that occurred on splice site, start codon, or stop codon.
The MutSig2CV (Cancer Genome Atlas Research Network, 2011) was applied to the quality-controlled mutation data to evaluate
significance of mutated genes and estimate mutation densities of samples. MutSig2CV combines evidence from background muta-
tion rate, clustering of mutations on hotspots and conservation of mutated sites to calculate the false discovery rates (q values).
Genes of q value < 0.1 were declared significant.
Microsatellite Instability
DNA samples were evaluated for Microsatellite Instability using theMSI-Mono-Dinucleotide assay, which examines four mononucle-
otide repeat loci (polyadenine tracts BAT25, BAT26, BAT40 and transforming growth factor receptor type II) and three dinucleotide
repeat loci (CA repeats in D2S123, D5S346 and D17S250).
Somatic Copy Number Alterations
DNA from each tumor or germline sample was hybridized to Affymetrix SNP 6.0 arrays using protocols from the Genome Analysis
Platform of the Broad Institute as previously described (McCarroll et al., 2008). From raw .CEL files, Birdseed was used to infer a
preliminary copy-number at each probe locus (Korn et al., 2008). For each tumor, genome-wide copy-number estimates were refinede3 Cancer Cell 33, 721–735.e1–e8, April 9, 2018
using tangent normalization, in which tumor signal intensities are divided by signal intensities from the linear combination of all normal
samples that are most similar to the tumor. This linear combination of normal samples tends to match the noise profile of the tumor
better than any set of individual normal samples, thereby reducing the contribution of noise to the final copy-number profile. Individual
copy-number estimates then underwent segmentation using Circular Binary Segmentation (Olshen et al., 2004). Segmented copy-
number profiles for tumor andmatched control DNAswere analyzed using Ziggurat Deconstruction, an algorithm that parsimoniously
assigns a length and amplitude to the set of inferred copy-number changes underlying each segmented copy number profile, and the
analysis of broad copy-number alterations was then conducted as previously described (Mermel et al., 2011). Significant focal copy-
number alterations were identified from segmented data using GISTIC 2.0 (Mermel et al., 2011). Allelic copy number, regions of ho-
mozygous deletions, whole genome doubling and purity and ploidy estimates were calculated using the ABSOLUTE algorithm
(Carter et al., 2012).
Copy ratios of the genomic segments were adjusted by purity and ploidy using the In Silico Admixture Removal (ISAR) method
(Carter et al., 2012). The tumor purity and ploidy were estimated with ABSOLUTE (Absolute quantification of somatic DNA alterations
in human cancer (Carter et al., 2012). GISTIC 2.0 (Mermel et al., 2011) was used to identify significant genomic regions, and q values
that were smaller than 0.1 were considered significant. The gene under selective pressure in each significant amplification/deletion
peak was manually curated with consideration of the common fragile sites (CFS). The gene-level copy numbers were obtained from
GISTIC, and the gene was considered as amplified or deleted if the gene-level copy number change (ploidy-adjusted) was larger
than 2 or smaller than -1.3, respectively. Whole-genome doubling (WGD) calls, absolute allelic copy numbers, and clonal statuses
of the SCNAs were all obtained from ABSOLUTE.
Aneuploidy Scores
The aneuploidy scores were calculated to quantify various kinds of aneuploidy in terms of length and magnitude of the copy-number
events including segment gains and losses. The aneuploidy scores in this study were obtained as follows: (1) the original copy ratios
of the genomic segments were adjusted by purity and ploidy using the ISAR method as noted above; (2) GISTIC 2.0 was used to
deconstruct the ISAR-adjusted copy-number profile into SCNA events (discrete copy-number alterations), and each SCNA event
could be categorized based on its length and magnitude (with details below); (3) for each category of SCNA events, e.g., focal am-
plifications, the corresponding aneuploidy score was calculated as log10ð1 + nÞ, where n is the number of events in that category.
Similar approaches to the aneuploidy scores in principle were applied in a recent study (Davoli et al., 2017) as well as in our previous
study (Dulak et al., 2012). The categories of SCNA events were defined as (1) Arm-level events: the relative SCNA length (as a
proportion to the arm length) larmR0:5, and the absolute value of amplitude jmj>0:3, and the threshold of 0.3 was applied to remove
low copy ratio changes that were likely noise; (2) Focal events: larm<0:5, jmj>0:3; (3) Focal amplifications: larm<0:5, m>0:3; (4) Focal
deletions: larm<0:5,m< 0:3; (5) High-level focal amplifications: larm<0:5,m>1; (6) Deep-level focal deletions: larm<0:5, m< 1. This
method serves as a quantification of different types of genomic aneuploidy, and it is different from the gene-level amplification and
deletion mentioned above, where conservative thresholds (2 and -1.3) for the gene-level copy number (not SCNA events) were
applied to define functional alterations of the genes.
CIN-Focal Score
We developed a CIN-Focal (CIN-F) score to capture the most focal high-level amplicons (MFAs), which are likely to be functional
gains of specific genomic regions that were subject to positive selection during cancer evolution. Based on the deconstructed
copy-number events from GISTIC 2.0, we defined those MFAs as l<3 Mb and m>2, where l is the length of the amplicon in mega-
bases, andm is the event amplitude as mentioned above. Given each of those amplicons, the CIN-F score of a tumor was first calcu-
lated as the weighted sum of the magnitude ma of each amplicon a (weighted by its length la), and then log-transformation was
applied:
SCINF = log10

1+
X
a
la$ma

Becausema is the ploidy-adjusted amplitude of copy-number gain, la$ma is theoretically proportional to the relative amount of DNA
(compared to the total cancer DNA) of the amplicon a, so that the CIN-F score corresponds to the amount of additional DNAwithin the
MFAs. An alternative metric to CIN-F score is simply the total number of MFAs in a genome regardless of the lengths and amplitudes
of theMFAs. The CIN-F score showed a binomial distribution in the upper GI cancers. We used kernel density estimation of Gaussian
kernels (R statistical software, the ‘‘density’’ function) to set the threshold for dichotomization at the local minimum of estimated den-
sity of the CIN-F score, and this analysis yielded a threshold of SCIN-F = 0.438. The CIN tumors was then dichotomized into CIN-F and
CIN-B as shown in Figure 4C.
Clonal Deletion Score (CDS)
To identify tumors with chromosomal instability, we developed a score, termed the Clonal Deletion Score, or CDS, which quantifies
the number of clonally deleted genomic regions in each tumor’s genome. The CDS of each tumor was calculated using absolute
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as q1 and q2 for the two alleles with lower and higher copy number, respectively. If (1) the segment is a deletion, i.e., q1<q2, and q1 +
q2<t, where t is the average tumor ploidy; and (2) the deletion is clonal, i.e., q1 is a clonal copy number according to ABSOLUTE; then
the clonal deletion effect (CDE) of the segment is calculated as:
CDE= 2

1 q1 +q2
t

If a segment does not satisfy the above criteria, the CDE of that segment is zero. The copy number of the higher allele q2 was incor-
porated so as to diminish the CDE when there was a gain of the higher allele, e.g., copy-neutral loss of heterozygosity (LOH). Given
the CDE of each segment s, the CDS of a tumor is the average of CDE weighted by the lengths of the segments:
CDS=
X
s
ws$CDEs; ws =
lsP
sls
where ls is the length of a segment. The CDSs from the GI adenocarcinomas showed a clear bimodal separation. The kernel density
estimation approach asmentioned abovewas used to set the threshold for dichotomization of CDS. A threshold of CDS= 0.0249was
then applied for the binary CIN/GS classification (Figures 2B and S2B), which corresponds to distinct copy-number profiles as shown
in Figure S2C.
Mutational Signatures
Mutational signatures were identified from SNVs using a Bayesian version of the non-negative matrix factorization method as
described previously (Kim et al., 2016). The mutations were deconvoluted into distinct mutational signatures based on the number
of mutations partitioned by 6 base substitutions (C>A, C>G, C>T, T>A, T>C, and T>G) and 16 possible combinations of neighboring
bases that resulted in 96 possible types of mutations. A 96-by-M matrix of mutation counts (M is the number of samples) was con-
structed as the input data for signature discovery. Cosine similarity was used to evaluate the resemblance of the identified signatures
with the COSMIC signatures (http://cancer.sanger.ac.uk/cosmic/signatures). For each sample, the estimated number of mutations
from a signature was used as the intensity of that signature. A two-stage strategy of mutational signature discovery was performed in
this study to achieve more accuracy in the identification of signatures. In the first stage, all samples were used to identify the signa-
tures. In the second stage, the analysis was performed only for the non-hypermutated cases with the MSI and POLE signatures
removed from the mutation counts to facilitate identification of signatures in the non-HM population.
Stemness Index
Weused one-class logistic regression (Sokolov et al., 2016) to derive a stemness index based on a gene expression signature derived
from embryonic and differentiated cells from the PCBC dataset (Daily et al., 2017; Salomonis et al., 2016) and applied this to GIAC
samples using Spearman correlations between the model’s weight vector and the GIAC sample’s expression profile (Malta
et al., 2018).
Differential Gene Expression Analysis between GIAC and Non-GI AC
To identify genes differentially abundant in GIAC versus non-GI AC, excluding genes that are differentially expressed between normal
GI tissue compared to normal non-GI tissue, we needed to use external gene expression data from normal tissues. We selected 4
gastrointestinal (esophagus, stomach, colon-transverse, and colon-sigmoid) and 5 non-gastrointestinal (breast, lung, ovary, pros-
tate, and uterine) normal tissue types through GTEx repository of normal tissues (GTEx Consortium et al., 2017) (https://www.
gtexportal.org/home/datasets, GTEx Version 7), and utilized their RNA-sequencing expression dataset. Normalized expression
values for both TCGA tumor and GTEx normal tissue cases were calculated by robust scaling (on values between 2.5 and 97.5
percentile) and winsorizing of each gene’s expression (mean ± 3 standard deviations) in the respective case population of tumoral
or normal cases. Gastrointestinal and non-gastrointestinal normal tissues were selected based on the matching with composition
of available GI and non-GI adenocarcinomas in TCGA PanCancer project. Orthogonal partial least squares-discriminant analysis
(OPLS-DA) was used to discover a subgroup of genes (n=671) that were not differentially expressed in GI and non-GI normal tissues,
but were members of our list of differentially expressed genes between GI adenocarcinomas (GIAC) and non-GI adenocarcinomas
(Non-GI AC). Significance was determined by absolute loading in the OPLS discriminant analysis of higher than 0.05. The genes for
which expression was highly associated with the stromal class of GI tumors identified by the method described in Isella et al. (Isella
et al., 2015) (n=118) were excluded from further analysis (absolute loading higher than 0.05). By utilizing an OPLS-DA model
comparing GIAC and non-GI AC cases, the remaining 553 genes were ranked by their loadings toward overexpression in GIAC. Re-
sults were depicted in two heatmaps illustrating the normalized expression values for the selected genes in both GIAC and non-GI AC
tissues, and normal GI and non-GI tissues, respectively (Figure S1G).
Selection of Transcription Factors for Gain- and Loss-of-function Studies
We used multiple sources to select 139 transcription factors (TFs) that are important in GI development. We first identified 40 TFs
in the Gene Ontology (GO) database based on the intersection of two GO terms, RNA polymerase II transcription factor activity,
sequence-specific DNA binding (GO: 0000981) and digestive tract development (GO: 0048565), in Homo sapiens. Further, wee5 Cancer Cell 33, 721–735.e1–e8, April 9, 2018
collected 24 TFs from the review by Noah et al. on human intestinal development and differentiation (Noah et al., 2011). Additionally,
93 genes were identified in the study in which Sherwood and colleagues used microarray and dynamic immunofluorescence tech-
nologies to profile gene expression during mouse endodermal organ formation (Sherwood et al., 2009). Finally, we also included nine
other TFs that were significantly mutated in GIAC. In all, we examined 139 genes (taking the union of the four gene lists and removing
genes with missing platform data).
DNA Methylation Data
Illumina Infinium DNA methylation arrays [including both HumanMethylation27 (HM27) and HumanMethylation450 (HM450)] were
used to assay 921 GIAC and 76 adjacent non-malignant tissues. Level 3 data from two generations of Illumina infinium DNA methyl-
ation arrayswere combined and further normalized between platforms using a probe-by-probe proportional rescalingmethod as out-
lined below to yield a final common set of 22,601 probes with comparative methylation levels between platforms. During data gen-
eration, a single technical replicate of the same cell line control sample from either of two different DNA extractions (TCGA-07-0227/
TCGA-AV-A03D) was included on each plate as a control, and measured 44/198 times and 12/169 times on HM27 and HM450,
respectively. These repeated measurements were therefore used for rescaling of the HM27 data to be comparable to HM450. For
each probe within each platform, we computed the median b value across all technical replicates of each of the two TCGA IDs.
We then combined the two extractions by taking the mean of the two medians obtained for each of the two replicate TCGA IDs,
and obtained a single summarized DNA methylation read-out (b value) for the corresponding probe i for each platform, noted as
Betahm27;i; and Betahm450;i; respectively. We then applied a constrained (within the range of 0 to 1 for b values) linear rescaling of
the HM27 data for each probe and for each patient’s sample using Betahm27;i and Betahm450;i. When the HM27 b value of a patient’s
sample j for probe iwas smaller than themean ofmedian replicate samples on theHM27 for that probe, we linearly rescaled theHM27
b value Betahm27,i,j in the (0, Betahm27,i,j ) space; and when Betahm27,i,j was greater, we linearly rescaled the HM27 beta value
Betahm27,i,j in the (Betahm27,i,j ,1) space; This translates into the following mathematical computation: Beta hm450;i;j =
Betahm27;i;j  ðBetahm450;i=Betahm27;iÞ, if Betahm27;i;j<Betahm27;i; and Beta hm450;i;j = 1 ð1 Betahm27;i;jÞ  ðð1 Betahm450;i Þ=
ð1 Betahm27;iÞÞ, if Betahm27;i;j > Betahm27;i.
After the between-platform normalization, we further excluded 779 probes that still showed a consistent platform difference
(mean b value difference greater than or equal to 0.1) in six or more tumor types.
Unsupervised Clustering Analysis of DNA Methylation Data
Unsupervised clustering analyses of DNAmethylation data were performed based on promoter CpG sites that did not exhibit tissue-
specific DNA methylation in normal tissues and blood cells (mean b value < 0.2 for each tissue type), but acquired methylated in
tumors.
GIAC and Non-GI AC
We analyzed DNA methylation profiles of 3,759 adenocarcinomas including 921 GI adenocarcinomas and 2,828 non-GI adenocar-
cinomas representing 12 disease types (four GIAC and eight non-GI AC) (Figure S1A). We also included data from 333 histologically
normal tumor-adjacent tissue specimens corresponding each disease type (BRCA n=101, PRAD n=39, OV n=12, CEAD n=1, UCEC
n=43, EAC/GAC n=33, COAD n=37, READ n=6, CHOL n=9, PAAD n=10, LUAD n=42). We first used the data from the normal
tissues and leukocytes to select CpG sites that lacked tissue-specific DNA methylation (mean b value < 0.2 in any tissue type and
b value >0.3 in nomore than five samples across the entire set). We then performed clustering analysis of the adenocarcinomas using
2,783 CpG sites that were hypermethylated (b value R0.3) in more than 10% within any of the 12 disease types. To minimize the
influence of tumor purity on a clustering result, we dichotomized the data using a b value ofR0.3 to define positive DNAmethylation
and < 0.3 to specify lack of methylation. We applied hierarchical clustering with Ward’s method to cluster the distance matrix
computed with the Jaccard index. Heatmap was generated based on the original b values for 1,000 loci (a subset of 2,783 loci)
with the highest standard deviation in DNA methylation measurements among all adenocarcinomas.
GIAC (Figure 2D)
We analyzed DNA methylation profiles of 921 GIAC and 77 (33 gastric and 44 colorectal) histologically normal tumor-adjacent tissue
specimens. The precise locations within the GI organs from which the normal-adjacent tissue specimens were excised are not avail-
able. Unsupervised clustering of GIAC was performed based on 2,845 gene promoter loci unmethylated in normal tissues and leu-
kocytes (mean b value < 0.2 in both normal gastric and colorectal tissues) but methylated (b value > 0.3) more than 5% in at least one
of the GIAC tumor types. To minimize the influence of tumor purity, we dichotomized the data into 0’s and 1’s using a b value
threshold of 0.3. The optimal number of clusters was assessed based on 80% probe and tumor resampling over 1,000 iterations
of hierarchical clustering for K = 2, 3, 4.20 using the binary distance metric for clustering and Ward’s method for linkage as imple-
mented in the R/Bioconductor ConsensusClusterPlus package. The heatmap was generated using the original b values. The probes
were displayed based on the order of unsupervised hierarchal clustering of the b values using the Euclidean distance metric and
Ward’s linkage method.
The Union of MSI and CIMP-H GIAC (Figure 3B)
We used 158 tumors (93 GEA and 65 CRC) that were classified as either CIMP-H or MSI and 44 normals (12 stomach and 32 colo-
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lacking DNA methylation in normal tissues (mean b value < 0.2 in both normal gastric and colorectal tissues) and methylated
(b value > 0.3) more than 10% in any of the tumor type. Heatmap was generated based on the top 10% of the most variably hyper-
methylated sites across 158 GIAC.
GIAC DNA Hypermethylation Subtypes
We chose sevenGIACDNAmethylation clusters defined by the consensus clustering. For further integrative analyses, we focused on
four prominent clusters showing a high frequency of cancer-associated DNA hypermethylation. We found that the gastroesophageal
(GEA) and colorectal adenocarcinomas (CRC) largely clustered separately. Among GEA, EBV+ gastric cancers stood out from all the
rest by their extensive DNA hypermethylation (cluster 4) and were designated as EBV-CIMP as in the previous study (Cancer
Genome Atlas Research Network, 2014). Cluster 5 is significantly enriched for MSI tumors originating in both stomach and colon.
It included well-known CIMP-High CRC associated with BRAFV600E mutations and MSI-associated Gastric-CIMP described previ-
ously (Cancer Genome Atlas Research Network, 2014; Weisenberger et al., 2006). We classified these tumors as GIAC CIMP-H, as
having a higher prevalence of DNA hypermethylation than all the other clusters with the exception of EBV-CIMP. Further, we named
cluster 6 as CRC CIMP-L that exhibited features consistent with CIMP-Low subtype previously described (Cancer Genome Atlas
Research Network, 2012). It had a significant association with KRAS mutations (p < 2.2 3 10-16 [vs. CRC in other groups], Fisher’s
exact test). Among GEA, cluster 1 was enriched for esophageal tumors (p = 8.0 3 10-8 [vs. GEAs in other groups]), and also had a
meanDNA hypermethylation frequency slightly higher than that in CRCCIMP-L and other GEA clusters (cluster 2 and 3).We specified
these tumors as GEA-CIMP-L. These tumors showed frequent epigenetic silencing of tumor suppressor genes including CDKN2A
and MGMT (p = 1.5 3 10-10 and p = 1.5 3 10-11, respectively, [vs. GEA clusters 2 and 3]).
Identification of Epigenetically Silenced Genes
Weused 775GIAC and 44 adjacent non-malignant tissues assayed on the HM450 platform. Probes locatedwithin potential promoter
regions (1500 bp flanking regions upstream and downstream of Transcription Start Sites (TSSs) of all transcripts annotated by UCSC)
were examined for evidence of epigenetic silencing. We removed the CpG sites that were methylated in normal tissues and blood
cells (mean b value > 0.2 for each tissue type). In order to remove the effect of tissue specificity on gene expression, we z-score-trans-
formed log 2 gene expression data first within each cancer type. The z-scores were derived using the mean and standard deviation
calculated with the unmethylated tumors only, defined as those with a b value of (0, 0.2). Samples across all the cancer types
were then pooled. For each probe/gene pair, we chose the probes that exhibited epigenetic silencing with the following
criteria: 1) at least 8 samples (>1% of all tumors) were observed with a b value of 0.3 or above (defined as the methylated group);
2) mean z-score of the methylated group was lower than -1.65; 3) FDR-corrected p value according to one-side t-test on z-scores
was lower than 0.001 between the unmethylated and methylated groups. Probes surviving these steps were retained to call epige-
netic silencing events based on DNA methylation profiles for each sample. If there were multiple probes associated with the same
gene, a sample identified as epigenetically silenced at more than half the probes for the corresponding gene was also labeled as
epigenetically silenced at the gene level.
CDKN2A epigenetic silencing calls were made using the exon-level RNA-seq data. CDKN2A DNA methylation status was as-
sessed in each sample, based on the probe (cg13601799) located in the p16INK4 promoter CpG island. p16INK4 expression was
determined by the log2(RPKM+1) level of its first exon (chr9: 21974403-21975132). The epigenetic silencing calls for each sample
weremade by evaluating a scatter plot showing an inverse association betweenDNAmethylation and expression. ForRAD51C, there
was no common probe betweenHM27 andHM450 that was located in the promoter region. However, probe cg14837411 fromHM27
and probe cg27221688 from HM450 were only 100bp apart, and both correlated with gene expression. Therefore, we combined
them in determining the silencing status of this gene. Samples with a b value of 0.2 or above for either probe were designated as
cases with epigenetic silencing.
DNA Hypermethylation Frequency in GIAC and Non-GI AC
We identified a set of 13,809 CpG sites that were unmethylated in normal tissues and blood cells (mean b value < 0.2 for each tissue
type). For each CpG locus, tumors with a b value of 0.3 or greater were designated as methylated, and tumors with a b value of lower
than 0.3 were designated as unmethylated. We then calculated the percentage of loci that were methylated among the loci investi-
gated in each tumor.
Methods for Integrative Pathway Analysis
We evaluated somatic mutations and copy-number changes relevant to well-studied signaling pathways curated in previous TCGA
publications. Oncogenic relevancewas assessed usingOncoKB, a knowledge base for the oncogenic effects of cancer genes, that is
manually curated by researchers and physicians at Memorial Sloan Kettering (Chakravarty et al., 2017). Specifically, a mutation was
counted and included in the diagrams if either (1) it had been reported as a recurrent alteration in COSMIC (Forbes et al., 2011) or (2) it
had been labeled as oncogenic or likely oncogenic in OncoKB. Amplifications and deep deletions were based on GISTIC calls and
reflect a change ofmore than half of the baseline gene copies. The actual list of oncogenic and likely oncogenic alterations is regularly
updated based on the literature; the most recent version can be retrieved online from the OncoKB public website (www.oncokb.org)
or visualized when viewing the data in the cBioPortal (www.cbioportal.org). For known oncogenes, only genetic alterations inferred to
be activating were considered; for tumor suppressor genes, only alterations inferred to be inactivating were considered.e7 Cancer Cell 33, 721–735.e1–e8, April 9, 2018
QUANTIFICATION AND STATISTICAL ANALYSIS
We used Fisher’s exact test for independence between two categorical variables throughout the analyses. Wilcoxon rank-sum test
was performed for any independence test between a continuous variable and a binary categorical variable. For any test between two
continuous variables or any association test that needed to be adjusted by covariates, a (multiple) linear model was fitted to evaluate
the significance of coefficients, and analysis of variance was used to calculate the proportion of variance explained by each variable.
Non-negative variables that were heavily right-skewed, which included the aneuploidy scores, CIN-F score, number ofMFAs, and the
intensities of mutational signatures, were log-transformed (with a pseudo-count of 1 added) for appropriate fitting of multiple linear
models. For the association test between aneuploidy scores and BRCA signature, the arm-level score and focal score were simul-
tenously included as explanatory variables in the multiple linear model. The association test between BRCA signature and PARP1
expression (log-transformed) was adjusted by the copy number of PARP1. The intensity of the CpG>TpG signature was modeled
by multiple linear regression with explanatory variables of upper/lower GI, molecular subtype, age, and CIMP status as an ordinal
variable. A logistic regression model was fitted when the response variable was binary. The test between the CIN-F score and clinical
stage was performed using an ordered logit model as the clinical stage was considered an ordinal variable, and the p values were
calculated using normal approximation. The association test between number of MFAs and the CRC stromal subtype was performed
using negative-binomial regression that models the sparse number of MFAs, so as to increase statistical power. Cox regression
was used for survival analysis to evaluate the significance of the variables. All statistical analyses in this study were performed using
the R statistical software (https://www.r-project.org).
DATA AND SOFTWARE AVAILABILITY
The raw data, processed data and clinical data can be found at the legacy archive of the GDC (https://portal.gdc.cancer.gov/legacy-
archive/search/f) and the PancanAtlas publication page (https://gdc.cancer.gov/about-data/publications/pancanatlas). The muta-
tion data can be found here: (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also be explored through
the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) and the Memorial Sloan Kettering Cancer Center cBioPortal
(http://www.cbioportal.org). Details for software availability are in the Key Resource Table.Cancer Cell 33, 721–735.e1–e8, April 9, 2018 e8
